BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 35012639)

  • 1. Artificial intelligence framework identifies candidate targets for drug repurposing in Alzheimer's disease.
    Fang J; Zhang P; Wang Q; Chiang CW; Zhou Y; Hou Y; Xu J; Chen R; Zhang B; Lewis SJ; Leverenz JB; Pieper AA; Li B; Li L; Cummings J; Cheng F
    Alzheimers Res Ther; 2022 Jan; 14(1):7. PubMed ID: 35012639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interpretable deep learning translation of GWAS and multi-omics findings to identify pathobiology and drug repurposing in Alzheimer's disease.
    Xu J; Mao C; Hou Y; Luo Y; Binder JL; Zhou Y; Bekris LM; Shin J; Hu M; Wang F; Eng C; Oprea TI; Flanagan ME; Pieper AA; Cummings J; Leverenz JB; Cheng F
    Cell Rep; 2022 Nov; 41(9):111717. PubMed ID: 36450252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multimodal single-cell/nucleus RNA sequencing data analysis uncovers molecular networks between disease-associated microglia and astrocytes with implications for drug repurposing in Alzheimer's disease.
    Xu J; Zhang P; Huang Y; Zhou Y; Hou Y; Bekris LM; Lathia J; Chiang CW; Li L; Pieper AA; Leverenz JB; Cummings J; Cheng F
    Genome Res; 2021 Oct; 31(10):1900-1912. PubMed ID: 33627474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AlzGPS: a genome-wide positioning systems platform to catalyze multi-omics for Alzheimer's drug discovery.
    Zhou Y; Fang J; Bekris LM; Kim YH; Pieper AA; Leverenz JB; Cummings J; Cheng F
    Alzheimers Res Ther; 2021 Jan; 13(1):24. PubMed ID: 33441136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Harnessing endophenotypes and network medicine for Alzheimer's drug repurposing.
    Fang J; Pieper AA; Nussinov R; Lee G; Bekris L; Leverenz JB; Cummings J; Cheng F
    Med Res Rev; 2020 Nov; 40(6):2386-2426. PubMed ID: 32656864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Artificial intelligence for drug discovery and development in Alzheimer's disease.
    Qiu Y; Cheng F
    Curr Opin Struct Biol; 2024 Apr; 85():102776. PubMed ID: 38335558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathway-based integration of multi-omics data reveals lipidomics alterations validated in an Alzheimer's disease mouse model and risk loci carriers.
    Garcia-Segura ME; Durainayagam BR; Liggi S; Graça G; Jimenez B; Dehghan A; Tzoulaki I; Karaman I; Elliott P; Griffin JL
    J Neurochem; 2023 Jan; 164(1):57-76. PubMed ID: 36326588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Scope of new formulation approaches in the repurposing of pioglitazone for the management of Alzheimer's disease.
    Jojo GM; Kuppusamy G
    J Clin Pharm Ther; 2019 Jun; 44(3):337-348. PubMed ID: 30738020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying candidate genes and drug targets for Alzheimer's disease by an integrative network approach using genetic and brain region-specific proteomic data.
    Liu A; Manuel AM; Dai Y; Fernandes BS; Enduru N; Jia P; Zhao Z
    Hum Mol Genet; 2022 Sep; 31(19):3341-3354. PubMed ID: 35640139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combinational Drug Repurposing from Genetic Networks Applied to Alzheimer's Disease.
    Nabirotchkin S; Bouaziz J; Glibert F; Mandel J; Foucquier J; Hajj R; Callizot N; Cholet N; Guedj M; Cohen D
    J Alzheimers Dis; 2022; 88(4):1585-1603. PubMed ID: 35811522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deep post-GWAS analysis identifies potential risk genes and risk variants for Alzheimer's disease, providing new insights into its disease mechanisms.
    Wang Z; Zhang Q; Lin JR; Jabalameli MR; Mitra J; Nguyen N; Zhang ZD
    Sci Rep; 2021 Oct; 11(1):20511. PubMed ID: 34654853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of type 2 diabetes GWAS loci and the risk of Parkinson's and Alzheimer's diseases.
    Chung SJ; Kim MJ; Kim J; Ryu HS; Kim YJ; Kim SY; Lee JH
    Parkinsonism Relat Disord; 2015 Dec; 21(12):1435-40. PubMed ID: 26499758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic Drug Repositioning for Alzheimer's Disease Based on Epigenetic Targets in Human Interactome.
    Chatterjee P; Roy D; Rathi N
    J Alzheimers Dis; 2018; 61(1):53-65. PubMed ID: 29199645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genome-wide network-based pathway analysis of CSF t-tau/Aβ1-42 ratio in the ADNI cohort.
    Cong W; Meng X; Li J; Zhang Q; Chen F; Liu W; Wang Y; Cheng S; Yao X; Yan J; Kim S; Saykin AJ; Liang H; Shen L;
    BMC Genomics; 2017 May; 18(1):421. PubMed ID: 28558704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Functional Pipeline of Genome-Wide Association Data Leads to Midostaurin as a Repurposed Drug for Alzheimer's Disease.
    Esteban-Martos A; Brokate-Llanos AM; Real LM; Melgar-Locatelli S; de Rojas I; Castro-Zavala A; Bravo MJ; Mañas-Padilla MDC; García-González P; Ruiz-Galdon M; Pacheco-Sánchez B; Polvillo R; Rodriguez de Fonseca F; González I; Castilla-Ortega E; Muñoz MJ; Rivera P; Reyes-Engel A; Ruiz A; Royo JL
    Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unraveling the intercellular communication disruption and key pathways in Alzheimer's disease: an integrative study of single-nucleus transcriptomes and genetic association.
    Liu A; Fernandes BS; Citu C; Zhao Z
    Alzheimers Res Ther; 2024 Jan; 16(1):3. PubMed ID: 38167548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computational Drug Repurposing for Alzheimer's Disease Using Risk Genes From GWAS and Single-Cell RNA Sequencing Studies.
    Xu Y; Kong J; Hu P
    Front Pharmacol; 2021; 12():617537. PubMed ID: 34276354
    [No Abstract]   [Full Text] [Related]  

  • 18. Shared genetic etiology underlying Alzheimer's disease and type 2 diabetes.
    Hao K; Di Narzo AF; Ho L; Luo W; Li S; Chen R; Li T; Dubner L; Pasinetti GM
    Mol Aspects Med; 2015; 43-44():66-76. PubMed ID: 26116273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug repurposing on Alzheimer's disease through modulation of NRF2 neighborhood.
    Bourdakou MM; Fernández-Ginés R; Cuadrado A; Spyrou GM
    Redox Biol; 2023 Nov; 67():102881. PubMed ID: 37696195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic druggable genome-wide Mendelian randomisation identifies therapeutic targets for Alzheimer's disease.
    Su WM; Gu XJ; Dou M; Duan QQ; Jiang Z; Yin KF; Cai WC; Cao B; Wang Y; Chen YP
    J Neurol Neurosurg Psychiatry; 2023 Nov; 94(11):954-961. PubMed ID: 37349091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.